This study aimed to compare the characteristics of patients with hematologic malignancies and solid cancers who received palliative care. A total of 124 patients with hematologic malignancy and 3032 patients with solid cancer, who received palliative care consultation services between 2006 and 2010 in a medical center in Taiwan, were retrospectively analyzed. Higher prevalence of oral stomatitis, diarrhea, and hematologic symptoms including infection, fever, severe anemia, and bleeding, and lower prevalence of constipation, abdominal distension, and pain were observed in patients with hematologic malignancies compared to that in patients with solid cancer. The interval from hospital admission to palliative care referral was longer for patients with hematologic malignancy than that for patients with solid cancer. Hematologists should refer patients earlier, and palliative care specialists should understand the specific needs of patients with hematologic malignancy.
Introduction
Hematologic malignancy is a special cancer entity compared to solid cancer and is characterized by systemic tumor involvement and diverse clinical manifestations. Patients with hematologic malignancy often present with symptoms related to bone marrow failure such as infection, bleeding, and anemia rather than direct compression by solid tumor. Some patients with hematologic malignancy do not realize how sick they are because the disease is not as apparent as some solid cancers.
The clinical course for hematologic malignancy varies widely. 1, 2 Patients with low-grade lymphoma often present with indolent symptoms, and they survive long term without requiring antitumor therapy. In contrast, patients with some subtypes of lymphoma or acute leukemia present with rapidly declining health and symptoms that resist any treatment. Although it is possible for some patients to survive long term after intensive treatment, they may experience severe sepsis or catastrophic bleeding as a result of chemotherapy-related myelosuppression. The curative rate increases when more intensive chemotherapy is prescribed, but patients are at higher risk of treatment-related complications and even death. Because dual potential exists for rapid clinical decline or ultimate cure, a great number of patients with hematologic malignancy may underestimate the possibility of imminent death during the course of intensive antitumor treatment. For patients with hematologic malignancies who experience resistance or intolerance to intensive therapy or disease relapse, the goal of treatment is to provide supportive care to ensure adequate symptom relief. The prognosis for these patients is still difficult to predict, because some life-threatening events such as infection or bleeding can be treated successfully with antibiotics or blood product transfusions. Due to these indeterminacies, there is weak but consistent evidence that palliative care is used less in hematologic malignancy cases and that more patients die in the acute setting compared to patients with solid cancer in Western countries. [3] [4] [5] [6] [7] According to the previous reports, distress symptoms are similar for patients with hematologic malignancy and solid cancer toward the end of life. 8 In 2003, the National Institute for Clinical Excellence (NICE) recommended including palliative care specialists in multidisciplinary hematological malignancy teams to provide integrated care for patients with hematological cancers. 9 The recent National Comprehensive Cancer Network guidelines for palliative care recommended that all patients with cancer be screened for palliative care needs as clinically indicated. 10 In 2009, cancer-related mortality was the leading cause of death in Taiwan, accounting for 25% of the total population deaths. 11 Palliative care services have been promoted in Taiwan for more than 2 decades in order to improve the quality of end-of-life care for terminally ill patients with cancer. In Taiwan, patients with hematologic malignancy rarely receive palliative care, in part because hematologic malignancy is a relatively rare cancer. Two of the most common hematologic malignancies, leukemia and nonHodgkin lymphoma, ranked 11th and 12th, respectively, as causes of cancer-related death, accounting for 4.7% of the total cancer death. Another barrier is the lack of understanding of patient characteristics and the lack of consensus on whether palliative care is required for patients with hematologic malignancies.
Data on the patterns and prevalence of distressing end-oflife symptoms in patients with hematologic malignancy are very limited in Taiwan. We retrospectively analyzed clinical characteristics of patients with hematologic malignancy and solid cancer who received palliative care consultation services at a medical center in Taiwan. This study aims to explore the similarities and differences between patients with hematologic malignancy and solid cancer who underwent palliative care to help inform the medical personnel who provide palliative care for patients with different disease entities.
Method

Patient Selection
A total of 3156 terminally ill patients with cancer who received palliative care consultation services between January 2006 and December 2010 at a single medical center in Northern Taiwan (Chang Gung Memorial Hospital at Linkou) were selected for this study. All the patients had either pathological-or radiographical-proven malignancies and were referred to palliative care consultation service on the basis of their clinicians' judgment that they would benefit from palliative care and were unlikely to live for 6 months. All patients were categorized either to the hematologic malignancies group (International Classification of Diseases, Ninth Revision, Clinical Modification codes 200-208) or to the solid cancer group based on the primary tumor localization. Patients referred from the emergency room or those undergoing curative-intent tumor treatment were excluded. The study protocol was approved by the hospital's institutional review board.
Palliative Care Consultation Service Setting and Data Collection
All participants were under the combined care of a primary care physician and an interdisciplinary palliative care team consisting of qualified physicians, specialist nurses, social workers, a Buddhist, and volunteers. The team members aimed to achieve better quality care at the end of life by controlling symptoms and providing holistic care for the patient and his or her family. Each patient was interviewed by a physician and a nursing specialist during the first consultation, with weekly follow-up interviews continuing until the end of service. Other specialists in the team would join the service upon request from the physician or nursing specialist. Services were terminated upon the patient's death, transfer to a hospice ward, refusal of further palliative care by the patient, or discharge from the hospital under stable conditions. Data consisted of patient demographics, patient assessments of distress, patient outcomes, and time intervals between the events. Patient demographics, including age, gender, marital status, education level, religious beliefs, and cancer type as well as physical symptoms, psychosocial distress, and spiritual needs were recorded by a specialist nurse using a formulated symptoms record form during the first consultation visit. This form was provided by the Bureau of Health Promotion in Taiwan and was chosen based on clinical experience with terminal cancer in Taiwan. [12] [13] [14] The primary caregiver answered questions about physical symptoms when the patient was unable to communicate. Fever was defined as blood temperature 38 C. Infection was defined as an evidence of local or systemic invasion by pathogens (bacterium, virus, or fungus). Severe anemia was defined as hemoglobin <8 g/dL. Psychosocial and spiritual needs were categorized as unable to be evaluated when a patient was either unable or refused to communicate.
Patient outcomes, including patient death, discharge due to terminal status, and place of discharge, were collected. The number of days between diagnosis, diagnosis of advanced cancer, hospital admission, and referral to a palliative care team was calculated, as was the number of days between referral to a palliative care team and death. Advanced cancer was defined as failure of curative intensive treatment or an inability to receive such treatment. The length of palliative care stay was calculated from the first day of palliative care referral to the date of palliative care completion. For outpatients, date of death was obtained from either the cancer registration center in our institute or the National Register of Death Database in Taiwan. Follow-up continued for all patients until death or the cutoff of this study on December 31, 2011.
Statistical Analysis
Statistical analyses were performed using SPSS 17.0 statistics software (SPSS, Inc, Chicago, Illinois). Basic demographic data were summarized as n (%) for categorical variables and medians with interquartile ranges (IQR, 25%-75%) for continuous variables, respectively. The prevalence of clinical symptoms was tabulated as n (%) by demographics and compared using the chi-square test. Differences between continuous variables were analyzed using t tests for normally distributed data and Wilcoxon rank-sum tests for nonnormally distributed data. All statistical assessments were considered significant at P < .05.
Results
Patient Demographics and Clinical Characteristics
Data for a total of 3156 patients, including 124 (3.9%) patients with hematologic malignancy and 3032 (96.1%) patients with solid cancer, were collected in the study (Table 1) . Patients with hematologic malignancies were younger (56.9 vs 59.3 years, P < .001) and had better Eastern Cooperative Oncology Group performance (performance status 1-2: 26% vs 13%, P < .001). More often, patients with hematologic malignancies were single (30% vs 8%, P < .001) and had nonspecific religious beliefs than patients with solid cancer (29% vs 19%, P ¼ .005). There was no between-group difference for gender or educational level. Acute leukemia (73%) and tumors in the hepatogastroenteral tract (48%) were the most prevalent primary diagnoses for patients with hematologic malignancy and solid cancer, respectively.
Prevalence of Symptoms
As seen in Table 2 , the first 3 leading physical distresses were breathlessness (51%), pain (48%), and fatigue (48%) for patients with hematologic malignancies, and pain (67%), constipation (63%), and breathlessness (59%) for patients with solid cancer. There was no difference in the prevalence of pulmonary, neurologic, and urologic symptoms between the 2 groups. Patients with hematologic malignancies had higher prevalence of oral stomatitis (13% vs 4%, P ¼ .006), diarrhea (6% vs 2%, P ¼ .049), and hematologic symptoms, including infection (32% vs 15%, P < .001), fever (24% vs 6%, P < .001), severe anemia (21% vs 5%, P < .001), and bleeding (13% vs 5%, P ¼ .009), as well as lower prevalence of constipation (41% vs 63%, P < 0.001), abdominal distension (13% vs 25%, P < .001), and pain (48% vs 67%, P < .001) than patients with solid cancer.
For psychosocial distress, 48% of the patients with hematologic malignancies and 47% of the patients with solid cancer either did not have or were unable to evaluate symptoms (P ¼ .81). Emotional disturbance and disease awareness and accommodation disturbance were the 2 leading psychosocial distress symptoms in patients with hematologic malignancy and solid cancer. The prevalence of psychosocial distress was not significantly different between the 2 groups except for a higher prevalence of emotional disturbance among patients with solid tumors (40% vs 29%, P ¼ .007). For spiritual demands, 69% of the patients with hematologic malignancy and 63% of the patients with solid cancer either had not experienced stress or were unable to evaluate this dimension. Existential solitude constituted the most prevalent spiritual demand for both the patient groups (24%). There were no betweengroup differences for all spiritual demands.
Patient Outcomes
Patient outcomes are summarized in Table 3 . Half of the patients (50% with hematologic malignancy and 48% with solid cancer) died either while receiving treatment or following discharge due to a terminal prognosis at the end of palliative care. Patient outcomes at the end of palliative care were similar between the 2 groups, except only 3% of the patients with hematologic malignancies were transferred to the hospice wards compared to 14% of patients with solid cancer (P < .000).
Time Interval of Events
The time interval of events is summarized in 
Discussion
A total of 124 (3.9%) patients with hematologic malignancy out of 3156 terminally ill patients with cancer were referred to palliative care consultation service in our institute between 2006 and 2010. The ratio of patients with hematologic malignancies who were referred to palliative care was lower than the ratio of hematologic malignancies associated with cancer death (4.7% in 2009) nationwide. 11 Patients with hematologic malignancies were younger, single, exhibited better performance status, and lacked specific religious beliefs compared to patients with solid cancer at the time of palliative care referral. However, patients with hematologic malignancies experienced similar physical symptoms, psychosocial distress, and spiritual demands at the end of life as patients with solid cancer. Among patients with solid cancer, pain, constipation, and abdominal distension were more prevalent than that among patients with hematologic malignancy. The prevalence of pain is reported in the literature at 52% to 84% [14] [15] [16] [17] among patients with solid cancer in the palliative care setting but just 27% to 76% among patients with hematologic malignancy. [18] [19] [20] The prevalence of pain in our study closely resembled to that in the previous reports. Patients with solid cancer had a higher prevalence of pain than patients with hematologic malignancy. A possible explanation for this difference is that tumor masses in patients with solid cancer may cause more symptoms. 18 Pain is one of the most distressing symptoms for terminally ill patients with cancer. The etiology of pain in patients with hematologic malignancies may be treatment or unavoidable tumor-related complications (ie, myeloma with pathologic bone fracture). Nearly, one-half (48%) of the patients with hematologic tumors in this study were experiencing tumor pain when they were referred to palliative care. Thus, medical staff should recognize pain in patients with hematologic malignancy just as they do in patients with solid cancer. The higher prevalence rate of constipation and abdominal distension among patients with solid cancer was related to the primary cancer origin being the hepatogastroenteral tract for 48% of the patients, and the fact that more opioids are prescribed for patients with solid cancer due to a higher prevalence of tumor pain.
Patients with hematologic malignancy inevitably had a significantly higher prevalence of hematologic symptoms than patients with solid cancer because of their disease entity. Stalfelt et al 18 reported that bleeding (44%) and infection (71%) were prevalent among 106 patients with acute myeloid leukemia in the final phase. Our data revealed a lower incidence of infection and bleeding observed at the time of palliative care referral, unlike the previous report. Infection (32%) and fever (24%) were the most prevalent hematologic symptoms in our study. Such a high incidence of infection highlights the importance of adequate supportive care including antibiotic treatment at the end of life for patients with hematologic malignancy. Because most patients with hematologic malignancy were immune compromised, they required broadspectrum and highly potent antibiotics to cover all possible (14) <.001 Refuse palliative care consultation service 6 (5) 147 (5) .990 Nursing home 6 (5) 121 (4) .640
infectious pathogens. A marked variability in the number and types of antibiotic prescriptions was reported in different palliative care settings during the last week of life. 21, 22 The role of antibiotics in terminally ill patients with cancer under palliative care is still a subject of much debate, and the debate is even more intense for patients with hematologic malignancy during end-of-life care. A prospective study is required in order to further explore this issue. Patients with hematologic malignancy also have higher prevalence rates for severe anemia and bleeding, managing both symptoms requires frequent blood product transfusions. Blood product support becomes essential for continued survival in the later stages of hematologic malignancy. The National Institute for Clinical Excellence highlights the necessity of enabling blood product support to be provided to patients in places other than hematology units. 9 Patients and family members may be reluctant to leave acute hematology units because of different policies between hematologists and palliative care specialists related to antibiotic prescriptions and blood product transfusions. 23, 24 This may explain why only 3% of the patients with hematologic malignancy were transferred to hospice wards at the end of palliative care consultation services in the study. Palliative care specialists should be aware of the importance of blood product support for maintaining adequate life quality in patients with hematologic malignancy and continuously weigh the advantages and disadvantages of blood product transfusion with patients and family members. Hematologists and palliative care specialists should consider the opinions of patients and family members based on clear treatment goals and desired outcomes when administering antibiotic treatment to patients with end-stage hematologic malignancy.
Emotional disturbance, disease awareness, and accommodation disturbance were reported as the most common manifestations of psychosocial distress among terminal patients with cancer in similar palliative care settings in Taiwan. 14, 25 Our study reported a similar pattern and prevalence of psychosocial distress among both patients with hematologic malignancy and patients with solid cancer. In this study, the prevalence of psychosocial distress was not significantly different between the 2 groups, except for a higher prevalence of emotional disturbance among patients with hematologic malignancy than those with solid cancer. An interim analysis of patient demographic data in this study showed that patients with better performance status, single marital status, and nonspecific or Buddhist religious beliefs experienced less emotional disturbance (data not shown). The lower incidence of emotional disturbance among patients with hematologic malignancy was attributed to patient characteristics rather than the disease itself. Only half of the patients had no psychosocial distress, and two-thirds of the patients had no spiritual demands. The prevalence rate of psychosocial distress among terminally ill patients with cancer was underestimated because evaluation was limited to the first palliative care consultation.
These results highlight the importance of palliative care for terminally ill patients with cancer. One of the important roles of a palliative care specialist is to cooperate with the primary care physician to provide direct care for alleviation of physical symptoms. Another important role is to identify patient's psychosocial distress and spiritual demands and use palliative care expertise to offer counseling and spiritual guidance.
Late referral to palliative care was reported among patients with hematologic malignancy. 4 Accounting for the median time from palliative care to patient death and median length of palliative care stay, in this study there was no difference in time to palliative care referral between patients with hematologic malignancy and patients with solid cancers. However, both groups of patients experienced late referral to palliative care based on the median time from advanced cancer diagnosis to palliative care referral. In a recent randomized controlled trial, patients with newly diagnosed metastatic nonsmall-cell lung cancer who received integrated early palliative care with standard oncologic care were found to have improved quality of life, improved mood, and longer median survival times. 26 Late referral limits the scope of palliative care to terminal care only. Early palliative care referrals may help oncologists and hematologists improve care and quality of life for patients with metastatic cancer by providing regular comprehensive physical, psychosocial, and spiritual distress screening and helping to find immediate solutions.
The median time from hospital admission to palliative care referral was longer for patients with hematologic malignancy (24.5 days vs 14 days, P < .001). Evidence suggests that hematologists are comfortable and willing to refer patients to palliative care and would refer for symptom control regardless of the illness stage. 27 A possible explanation for the late referrals is that accurately predicting appropriate timing for referral to palliative care for patients with hematologic malignancy is more difficult than that for patients with solid cancer. Patients with hematologic malignancy have fluctuating courses of illness because some patients continue to receive treatment with curative intent and the main causes of death in patients with hematologic malignancy are acute complications related to myelosuppression such as infection or catastrophic hemorrhage. Such uncertainty makes patients, family members, and medical professionals hesitant to request palliative care. When patients are referred to palliative care only after diseasedirected treatments are exhausted, the opportunity for proper evaluation of comprehensive and appropriate end-of-life care is missed. This illustrates the importance of obtaining a better understanding of the characteristics and prevalent symptoms among patients with hematologic malignancies toward the end of life, in Taiwan.
Our study had several limitations. First, our data collection and analysis processes were retrospective. Second, this study was conducted at a single site with a small sample size of patients with hematologic malignancy. Therefore, the study result may not represent the characteristics of the entire population. Because the study was limited by the number of patients, no subgroup analyses between different hematologic malignancies were addressed. Third, only the prevalence of distressing symptoms was evaluated and not the differences in symptom severity between patients with hematologic malignancy and solid cancer. Future prospective studies are necessary to address these limitations.
Conclusion
Our data show that patients with hematologic malignancy differ from patients with solid cancer in their symptoms and complications. Due to lack of experience, palliative care staff may neglect their particular health care demands (e.g., blood product transfusions, broad-spectrum antibiotics), which should be properly addressed. Patients with hematologic malignances need palliative care just as much as patients with solid cancer; however, hematologists tend to delay referrals and consequently, the quality of holistic care may be compromised. Palliative care specialists should learn about the characteristics and specific needs of patients with hematologic malignancies. In addition, hematologists should be aware that their patients need palliative care no less than the patients with solid tumors and should therefore refer patients early. Quality of life may be significantly improved through mutual learning and collaboration between palliative care specialists and hematologists.
